Severe drug-induced skin reactions: Clinical pattern, diagnostics and therapy;Schwere arzneimittelinduzierte hautreaktionen: Klinik, diagnostik und therapie

JDDG - Journal of the German Society of Dermatology

Volumn 7, Issue 2, 2009, Pages 142-162

  Mockenhaupt, Maja ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Acute generalized exanthematous pustulosis (AGEP); Generalized bullous fixed drug eruption (GBFDE); Severe drug induced skin reactions; Stevens Johnson syndrome (SJS); Toxic epidermal necrolysis (TEN)

Indexed keywords

ALLOPURINOL; AMINOPENICILLIN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CHLORHEXIDINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXPANTHENOL; DILTIAZEM; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LAMOTRIGINE; MACROLIDE; NEVIRAPINE; OCTENIDINE; OXICAM DERIVATIVE; PHENOBARBITAL; PHENYTOIN; PRISTINAMYCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SILVER NITRATE; STEROID; SULFONAMIDE; TERBINAFINE; UNCLASSIFIED DRUG;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; BULLOUS SKIN DISEASE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRESS SYNDROME; GENERALIZED BULLOUS FIXED DRUG ERUPTION; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC THERAPY; INTRAVENOUS ADMINISTRATION; PATHOGENESIS; PROGNOSIS; REVIEW; SCORING SYSTEM; SKIN BIOPSY; SKIN EXAMINATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME;

EID: 59349099200     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2008.06878.x     Document Type: Review

References (25)

1. Mockenhaupt M, Norgauer J. Schwere arzneimittelinduzierte Hautreaktionen. Aller-gologie 2001 9 : 419 432.
2. Roujeau JC, Bioulac-Sage P, Bourseau C, Guillaume JC, Bernhard P, Lok C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol 1991 127 : 1333 1338.
3. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996 15 : 250 257.
4. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Arch Dermatol 2002 138 : 1019 1024.
5. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993 129 : 92 96.
6. Sidoroff A, Halevy S, Bouwes Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP) - A clinical reaction pattern. J Cutan Pathol 2001 28 : 113 119.
7. Kardaun SH, Sidoroff A, Valeyrie-Allanore, Halevy S, Davidovici BB, Mockenhaupt M, Roujeau JC. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007, 156 (3 609 611.
8. Rzany B, Hering O, Mockenhaupt M, Schröder W, Goerttler E, Ring J, Schöpf F. Histopathological and epidemiological characteristics of patients with erythema exsudativum multiforme majus (EEMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Br J Dermatol 1996 135 (1 6 11.
9. Ziemer M, Wiesend CL, Vetter R, Weiss J, Blaschke S, Norgauer J, Mockenhaupt M. Cutaneous adverse drug reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2007 143 : 711 716.
10. Mockenhaupt M, Idzko M, Grosber M, Schöpf E, Norgauer J. Epidemiology of staphylococcal scalded skin syndrome in Germany. J Invest Dermatol 2005 124 : 700 703.
11. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epi-dermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008 128 (1 35 44.
12. Fagot JP, Mockenhaupt M, Bouwes Bavinck JN, Naldi L, Viboud C, Roujeau JC. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis -preliminary results of a case-control study. AIDS 2001 15 : 1 6.
13. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008 58 (1 25 32.
14. Sidoroff A, Dunant A, Viboud C, Halevy S, Bouwes Bavinck JN, Naldi L, Mockenhaupt M, Fagot JP, Roujeau JC. Risk factors for acute generalized exanthematous pustulosis (AGEP) - results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007 157 : 989 996.
15. Buettiker U, Keller M, Pichler WJ, Braathen LR, Yawalkar N. Oral Prednisolone induced acute generalized exanthematous pustulosis due to corticosteroids of group A confirmed by epicutaneous testing and lymphocyte transformation tests. Dermatology 2006 213 : 40 43.
16. Nassif A, Moslehi H, Le Gouvello S, Bagot M, Lyonnet L, Michel L, Boumsell L, Benussan A, Roujeau JC. Evaluation of the potenzial role of cytokines in toxic epidermal necrolysis J Invest Dermatol 2004 123 (5 850 855.
17. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes Bavnick JN, Sidoroff A, de Toma C, Schumacher M, Roujeau JC, Hovnanian A, Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenetics and Genomics 2008 18 (2 99 107.
18. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CSJ, Wu JY, C YT. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005 102 : 4134 4139.
19. Pichler WJ, Yawalkar N, Britschgi M, Depta J, Strasser I, Schmid S, Kuechler P, Naisbitt D. Cellular and molecular pathophysiology of cutaneous drug reactions. Am J Clin Dermatol 2002 3 (4 229 238.
20. Shiohara T, Ijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivation. Br J Dermatol 2007 156 : 1083 1084.
21. Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Toxic epidermal necrolysis (Lyell's syndrome). J Am Acad Dermatol 1991 23 : 1039 1058.
22. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998 282 : 490 493.
23. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. A prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003 139 : 33 36.
24. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000 115 : 149 153.
25. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008 58 (1 33 40.